RxDoctor Payments Data

Johnathan Williams, MD

Internal Medicine · Gastonia, NCNPI 1245201557

Payments from drug & device makers

$13,255in general payments, 2019–2025

Across 769 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$947
  • Bayer$877
  • Amgen$871
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,214100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)94$1,473
AstraZeneca54$1,116
Novo Nordisk71$1,022
Lilly USA, LLC50$947
Bayer58$877
Amgen50$871
Pfizer43$689
GSK26$442
Sanofi-aventis U.S. LLC23$412
Preventric Diagnostics, Inc.4$387
Johnson & Johnson24$374
Takeda Pharmaceuticals U.S.A., Inc.19$329
Esperion Therapeutics, Inc.16$317
Merck16$275
Aytu Biopharma, Inc.20$271
Boehringer Ingelheim13$219
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$218
Amarin Pharma, Inc.14$203
Tris Pharma Inc11$189
Idorsia Pharmaceuticals US Inc10$165
Biohaven Pharmaceutical Holding Company Ltd.8$159
Ironshore Pharmaceuticals Inc.8$154
Boston Scientific5$150
Sanofi Pasteur Inc.6$119
Otsuka America Pharmaceutical, Inc.4$96
Novartis5$91
Xeris Pharmaceuticals, Inc.5$86
Eisai Inc.6$85
Kowa Pharmaceuticals America, Inc.7$85
Supernus Pharmaceuticals, Inc.4$82
Nestle Healthcare Nutrition Inc.4$80
Paratek Pharmaceuticals, Inc.6$75
Abbott3$73
Genentech USA, Inc.4$71
Jazz Pharmaceuticals Inc.5$68
Phathom Pharmaceuticals, Inc.6$63
Lundbeck LLC3$58
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$55
Cranial Technologies, Inc3$54
Dexcom, Inc.2$46
Vanda Pharmaceuticals Inc.2$44
Hikma Pharmaceuticals USA2$39
Antares Pharma, Inc.2$36
Alk-abello, Inc2$36
Neos Therapeutics, LP2$31
Almatica Pharma LLC2$30
Seqirus USA Inc2$30
CSL Behring2$29
Exact Sciences2$28
Scilex Pharmaceuticals Inc.2$27
E.r. Squibb & Sons, L.L.C.2$27
Teva Pharmaceuticals USA, Inc.2$26
Sanofi1$24
Neurocrine Biosciences, Inc.1$22
Neurelis, Inc.1$21
Rhodes Pharmaceuticals L.p.1$21
Biohaven Pharmaceuticals, Inc.1$21
Adlon Therapeutics L.p.1$20
Insulet Corporation1$17
Lifescan, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,255 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$58,514
Medicare patients
153
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol158$105,554
KerendiaFinerenone76$66,006
EliquisApixaban55$55,423
XareltoRivaroxaban61$37,818
OzempicSemaglutide30$37,576
MounjaroTirzepatide19$21,370
AbrysvoRsv Vacc, Pref A And Pref B/Pf65$20,869
Tresiba Flextouch U-100Insulin Degludec36$19,451
VraylarCariprazine Hcl12$16,321
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,490
JardianceEmpagliflozin26$14,483
Tresiba Flextouch U-200Insulin Degludec19$14,041
Bydureon BciseExenatide Microspheres15$13,924
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,116$125,355196 claims
PfizerEliquis, Abrysvo$689$76,292120 claims
BayerKerendia$877$66,00676 claims
Johnson & JohnsonXarelto$374$37,81861 claims
Novo NordiskOzempic$1,022$37,57630 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta$442$26,73773 claims
Lilly USA, LLCMounjaro$947$21,37019 claims
Boehringer IngelheimJardiance, Stiolto Respimat$219$20,52639 claims
AbbVieVraylar, Synthroid$1,473$18,19532 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$412$10,69112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →